The management of infection with Mycobacterium tuberculosis in young children post-2015: an opportunity to close the policy-practice gap

Expert Review of Respiratory Medicine

Volumn 11, Issue 1, 2017, Pages 41-49

  Graham, Stephen M ^a,b,c  

^a MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^b INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^c BURNET INSTITUTE   (Australia)

Author keywords

child; contact screening; LTBI; preventive therapy; Tuberculosis

Indexed keywords

CHILD; DECENTRALIZATION; DIAGNOSTIC PROCEDURE; HEALTH CARE PLANNING; HEALTH CARE POLICY; HUMAN; INTEGRATIVE MEDICINE; MEDICAL TERMINOLOGY; MULTIDRUG RESISTANT TUBERCULOSIS; POLICY PRACTICE GAP; POLITICS; PRACTICE GAP; REVIEW; SCALE UP; SCREENING; TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; POINT OF CARE SYSTEM;

TUBERCULOSTATIC AGENT;

ANTITUBERCULAR AGENTS; CHILD; HUMANS; MYCOBACTERIUM TUBERCULOSIS; POINT-OF-CARE SYSTEMS; PROFESSIONAL PRACTICE GAPS; TUBERCULOSIS;

EID: 85006751049     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1080/17476348.2016.1267572     Document Type: Review

References (74)

1. World Health Organization. Global Tuberculosis Report 2016. Geneva, Switzerland:WHO; 2016.
2. Donald PR., Childhood tuberculosis:the hidden epidemic. Int J Tuberc Lung Dis. 2004;8(5):627–629.
3. Lestari T, Probandari A, Hurtig A-K, et al. High caseload of childhood tuberculosis in hospitals on Java Island, Indonesia:a cross-sectional study. BMC Public Health. 2011;11:784.
4. Graham SM, Sismanidis C, Menzies HJ, et al. Importance of tuberculosis control to address child survival. Lancet. 2014;383:1605–1607.
5. World Health Organization. Guidance for National Tuberculosis Programmes on the management of tuberculosis in children. second edition. Geneva, Switzerland:WHO; 2014.
6. World Health Organization. Guidelines on the management of latent tuberculosis infection. Geneva, Switzerland:WHO; 2015.
7. Hill PC, Rutherford ME, Audas R. van CR, Graham SM. Closing the policy-practice gap in the management of child contacts of tuberculosis cases in developing countries. Plos Med. 2011;8:e1001105.• Highlights the wide current policy-practice gap and provides a public health evaluation framework for evaluation and identification of the gaps in implementation.
8. Graham SM, Triasih R. More evidence to support screening of child contacts of tuberculosis cases:if not now, then when? Clin Infect Dis. 2013;57:1693–1694.
9. Marais BJ, Gie RP, Schaaf HS, et al. The natural history of childhood intra-thoracic tuberculosis:a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis. 2004;8(3):392–402.
10. Drobac PC, Shin SS, Huamani P, et al. Risk factors for in-hospital mortality among children with tuberculosis:the 25-year experience in Peru. Pediatrics. 2012;130:e373–e379.
11. Munoz-Sellart M, Yassin MA, Tumato M, et al. Outcome of children with tuberculosis in southern Ethiopia. Scand J Infect Dis. 2009;41(6–7):450–455.
12. Jaganath D, Zalwango S, Okware B, et al. Contact investigation for active tuberculosis among child contacts in Uganda. Clin Infect Dis. 2013;57:1685–1692.
13. Fox GJ, Barry SE, Britton WJ, et al. Contact investigation for tuberculosis:a systematic review and meta-analysis. Eur Respir J. 2013;41:140–156.
14. Gomes VF, Andersen A, Wejse C, et al. Impact of tuberculosis exposure at home on mortality among children less than 5 years old in Guinea Bissau. Thorax. 2011;66(2):163–167.
15. Du Preez K, Hesseling AC, Mandalakas AM, et al. Opportunities for chemoprophylaxis in children with culture-confirmed tuberculosis. Ann Trop Paed Int Child Health. 2011;31:301–310.
16. Donald PR. Edith Lincoln, an American pioneer of childhood tuberculosis. Pediatr Infect Dis J. 2013;32:241–245.
17. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc. 1970;26:28–106.
18. Hsu KH. Thirty years after isoniazid. Its impact on tuberculosis in children and adolescents. Jama. 1984;251:1283–1285.
19. Smieja MJ, Marchetti CA, Cook DJ, et al. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev. 2000;2:CD001363.
20. Cruz AT, Ahmed A, Mandalakas AM, et al. Treatment of latent tuberculosis infection in children. J Pediatr Infect Dis Soc. 2013;2(3):248–258.• Very comprehensive recent review of evidence for the treatment of tuberculosis infection in children considering and critically assessing a variety of regimens for use in children.
21. Yuen CM, Jenkins HE, Rodriguez CA, et al. Global and regional burden of isoniazid-resistant tuberculosis. Pediatrics. 2015;136(1):e50–e59.
22. Triasih R, Duke T, Robertson C, et al. A prospective evaluation of the symptom-based screening approach to the management of children that are contacts of tuberculosis cases. Clin Infect Dis. 2015;60:12–18.• Original, prospective cohort study evaluating the WHO symptom-based screening approach to child tuberculosis contact management at a primary care level in Indonesia, providing support for the feasibility of decentralized community-based child contact screening and preventive therapy.
23. Adjobimey M, Masserey E, Adjonou C, et al. Implementation of isoniazid preventive therapy in children aged under 5 years exposed to tuberculosis in Benin. Int J Tuberc Lung Dis. 2016;20(8):1055–1059.
24. Maritz ER, Montepiedra G, Liu L, et al. Source case identification in HIV-exposed infants and tuberculosis diagnosis in an isoniazid prevention study. Int J Tuberc Lung Dis. 2016;20(8):1060–1064.
25. Mathad JS, Gupta A. Tuberculosis in pregnant and postpartum women:epidemiology, management, and research gaps. Clin Infect Dis. 2012;55(11):1532–1549.
26. Hesseling AC, Cotton MF, Jennings T, et al. High incidence of tuberculosis among HIV-infected infants:evidence from a South African population-based study highlights the need for improved tuberculosis control strategies. Clin Infect Dis. 2009;48:108–114.
27. World Health Organization. Guidelines for intensified case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva, Switzerland:WHO; 2011.
28. World Health Organization. The End TB Strategy. Global strategy and targets for tuberculosis prevention, care and control after 2015. Geneva, Switzerland:WHO; 2014.
29. World Health Organization. Latent Tuberculosis Infection Taskforce terms of reference. Geneva, Switzerland:WHO; 2015. cited 2016 July1st. Available from:www.who.int/tb/challenges/task_force/en/-
30. World Health Organization. Report of the global consultation on the programmatic management of latent tuberculosis infection. Seoul, Republic of Korea. Geneva, Switzerland:WHO; 2016 cited 2016 April27-28
31. Stop TB Partnership. The paradigm shift 2016-2020. The Global Plan to End TB. Geneva, Switzerland:Stop TB Partnership; 2016.
32. WHO/IUATLD/CDC/UNICEF/TAG/USAID. Roadmap for childhood tuberculosis:towards zero deaths. Geneva, Switzerland:WHO; 2013.
33. Kruk A, Gie RP, Schaaf HS, et al. Symptom-based screening of child tuberculosis contacts:improved feasibility in resource-limited settings. Pediatrics. 2008;121(6):e1646–e1652.
34. Rutherford ME, Hill PC, Triasih R, et al. Preventive therapy in children exposed to Mycobacterium tuberculosis:problems and solutions. Trop Med Int Health. 2012;17:1264–1273.
35. Hall C, Sukijthamapan P, Dos Santos R, et al. Challenges to delivery of isoniazid preventive therapy in a cohort of children exposed to tuberculosis in Timor-Leste. Trop Med Int Health. 2015;20(6):730–736.
36. Rutherford ME, Ruslami R, Anselmo M, et al. Management of children exposed to Mycobacterium tuberculosis:a public health evaluation in West Java, Indonesia. Bull World Health Organ. 2013;91(12):932–994.
37. Triasih R, Robertson C, De Campo J, et al. An evaluation of chest X-ray in the context of community-based screening of child tuberculosis contacts. Int J Tuberc Lung Dis. 2015;19:1428–1434.
38. Mandalakas AM, Hesseling AC, Gie RP, et al. Modelling the cost-effectiveness of strategies to prevent tuberculosis in child contacts in a high-burden setting. Thorax. 2013;68(3):247–255.
39. Rekha B, Jagarajamma K, Chandrasekaran V, et al. Improving screening and chemoprophylaxis among child contacts in India’s RNTCP:a pilot study. Int J Tuberc Lung Dis. 2013;17(2):163–168.
40. Tadesse Y, Gebre N, Daba S, et al. Uptake of isoniazid preventive therapy among under-five children:TB contact investigation as an entry point. Plos ONE. 2016;11(5):e0156525.
41. Gomes VF, Wejse C, Oliveira I, et al. Adherence to isoniazid preventive therapy in children exposed to tuberculosis:a prospective study from Guinea-Bissau. Int J Tuberc Lung Dis. 2011;15(12):1637–1643.
42. Donald PR. Antituberculosis drug-induced hepatotoxicity in children. Pediatr Rep. 2011;3:e16.
43. Lobato MN, Jereb JA, Starke JR. Unintended consequences:mandatory tuberculin skin testing and severe isoniazid hepatotoxicity. Pediatrics. 2008;121(6):e1732–1733.
44. Garie KT, Yassin MA, Cuevas LE. Lack of adherence to isoniazid chemoprophylaxis in children in contact with adults with tuberculosis in Southern Ethiopia. Plos ONE. 2011;6:e26452.
45. Marais BJ, Van Zyl S, Schaaf HS, et al. Adherence to isoniazid preventive chemotherapy:a prospective community based study. Arch Dis Child. 2006;91:762–765.
46. Triasih R, Padmawati RS, Duke T, et al. A mixed-methods evaluation of adherence to preventive treatment among child tuberculosis contacts in Indonesia. Int J Tuberc Lung Dis. 2016;20(8):1078–1083.
47. Comstock GW, Baum C, Snider DE, Jr. Isoniazid prophylaxis among Alaskan Eskimos:a final report of the bethel isoniazid studies. Am Rev Respir Dis. 1979;119:827–830.
48. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155–2166.•• Original findings showing non-inferiority of a short combination regimen for the treatment of tuberculosis infection requiring weekly medication thereby reducing the need for 270 dosages of daily medication (9H) to 12 dosages weekly (3HP). Recognized as a potential ‘game-changer’ for implementation and uptake of treatment for tuberculosis infection.
49. Villarino ME, Scott NA, Weis SE, et al. Treatment for preventing tuberculosis in children and adolescents:a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr. 2015;169(3):247–255.• Original data with findings as above in children and adolescents showing the new regimen to be as effective, safer, and with superior adherence.
50. Bliven-Sizemore EE, Sterling TR, Shang N, et al. Thee months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI. Int J Tuberc Lung Dis. 2015;19(9):1039–1044.
51. Sterling TR, Scott NA, Miro JM, et al. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. Aids. 2016;30(10):1607–1615.
52. Cruz AT, Starke JR. Safety and adherence for 12 weekly doses of isoniazid and rifapentine for pediatric tuberculosis infection. Pediatr Infect Dis J. 2016;35(7):811–813.
53. Weiner M, Savic RM, Menzie WR, et al. Rifapentine pharmacokinetics and tolerability in children and adults treated once weekly with rifapentine and isoniazid for latent tuberculosis infection. J Pediatr Infect Dis Soc. 2014;3(2):132–145.
54. Shepardson D, Marks SM, Chesson H, et al. Cost-effectiveness of a 12-dose regimen for treating latent tuberculosis infection in the United States. Int J Tuberc Lung Dis. 2013;17(12):1531–1537.
55. Bright-Thomas R, Nandwani S, Smith J, et al. Effectiveness of 3 months of rifampicin and isoniazid chemoprophylaxis for the treatment of latent tuberculosis infection in children. Arch Dis Child. 2010;95:600–602.
56. Detjen A, Macé C, Perrin C, et al. Adoption of revised dosage recommendations for childhood tuberculosis in countries with different childhood tuberculosis burdens. Public Health Action. 2012;2(4):126–132.
57. Wang J-Y, Yang P-C. Does a rifamycin-containing preventive regimen increase rifampicin resistance? An unresolved concern. Int J Tuberc Lung Dis. 2016;20:998.
58. Balcells ME, Thomas SL, Godfrey-Faucett P, et al. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis. 2006;12:744–751.
59. Den Boon S, Matteelli A, Getahun H. Rifampicin resistance after treatment for latent tuberculosis infection:a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2016;20(8):1065–1071.• A timely meta-analysis that addresses an important consideration of public health risk when changing to shorter rifamycin-containing regimens. Studies included in the meta-analysis were undertaken in research conditions and accompanying editorial provides note of caution on the need for assessment of their use under programmatic conditions.
60. Yuen CM, Jenkins HE, Chang R, et al. Two methods for seting child-focused tuberculosis care targets. Public Health Action. 2016;6(2):83–96.
61. Pai M, Sotgiu G. Diagnostics for latent TB infection:incremental, not transformative progress. Eur Resp J. 2016;47:704–706.
62. Tebruegge M, Dutta B, Donath S, et al. Mycobacteria-specific cytokine responses detect TB infection and distinguish latent from active TB. Am J Resp Crit Care Med. 2015;192:485–492.
63. Nicol MP, Gnanashanmugam D, Browning R, et al. A blueprint to address research gaps in the development of biomarkers for pediatric TB. Clin Infect Dis. 2015;61(suppl3):S164–S172.
64. Zak DE, Penn-Nicholson A, Scriba TJ, et al. A blood RNA signature for tuberculosis disease risk:a prospective cohort study. Lancet. 2016;387(10035):2312–2322.
65. Aggerbeck H, Giemza R, Joshi P, et al. Randomised clinical trial investigating the specificity of a novel skin test (C-Tb) for diagnosis of M.tuberculosis infection. Plos One. 2013;8:e64215.
66. Hoff ST, Peter JG, Theron G, et al. Sensitivity of C-Tb:a novel RD-1-specific skin test for the diagnosis of tuberculosis infection. Eur Resp J. 2016;47:919–928.
67. Dodd PJ, Sismanidis C, Seddon JA. Global burden of drug-resistant tuberculosis in children:a mathematical modelling study. Lancet Infect Dis. 2016;16:1193–1201.
68. Harausz E, Garcia-Prats AJ, Schaaf HS, et al. Global treatment outcomes in children with paediatric MDR-TB:systematic review and meta-analysis. Int J Tuberc Lung Dis. 2015;19(suppl 2):S29.
69. Seddon JA, Fred D, Amanullah F, et al. Post-exposure management of multidrug-resistant tuberculosis contacts:evidence-based recommendations. Policy brief no. 1. Dubai, United Arab Emirates:Harvard Medical School Center for Global Health Delivery, Dubai; 2015.• An update on evidence from treating tuberculosis infection in contacts of MDR TB cases by using regimens containing a fluoroquinolone.
70. Seddon JA, Hesseling AC, Finlayson H, et al. Preventive therapy for child contacts of multidrug-resistant tuberculosis:a prospective cohort study. Clin Infect Dis. 2013;57(12):1676–1684.
71. Bamrah S, Brostrom R, Fred D, et al. Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012. Int J Tuberc Lung Dis. 2014;18(8):912–918.
72. Graham SM, Grzemska M, Brands A, et al. Regional initiatives to address the challenges of tuberculosis in children:perspectives from the Asia-Pacific region. Int J Infect Dis. 2015;32:166–169.
73. International Union Against Tuberculosis and Lung Disease. Childhood TB Learning Portal. Paris, France:The Union; 2016. Available from:https://childhoodtb.theunion.org/
74. World Health Organization. Childhood TB:Training Toolkit. Geneva, Switzerland:WHO; Available from:http://www.who.int/tb/challenges/childtbtraining_manual/en/